AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are ...

While digital health technologies (DHTs) offer potential new ways to collect data in clinical trials, industry stakeholders ...

California's life sciences industry, and some lawmakers, urge state leaders to reject budget proposal to permanently limit ...

The FDA real-time clinical trial model enables prospective safety monitoring, improving risk assessment and speeding oncology drug development.

From spaceflight to high-throughput studies, evidence supports greater use of organ chips, but regulatory ambiguity and ...

Incretin-based therapies are transforming the treatment of obesity and related comorbidities. This Review outlines the current landscape of obesity drug development, focusing on glucagon-like peptide ...

As leadership changes create more instability at the agency, here's what it'll take to keep speedier drug approvals on track.

FDA instability, staff turnover, and evolving review standards are reshaping drug development. Richard Pazdur, formerly with ...

Scott, a biotech entrepreneur, told CalMatters that reducing R&D tax credits could threaten hiring. The life sciences ...

Many promising therapies fail because preclinical models do not fully capture the complexity of the human heart. A new review ...

HkeyBio announced today the launch of preclinical disease model platforms covering Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and IgA Nephropathy (IgAN). This platform integrates ...